anti-PCSK9 DMAb

Anti-PCSK9 DMAb is a DNA-encoded monoclonal antibody (DMAb) designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). Developed by researchers at The Wistar Institute, this approach utilizes a synthetic DNA plasmid delivered via intramuscular injection followed by electroporation. Once inside the muscle cells, the DNA provides the genetic instructions for the body to produce and secrete functional monoclonal antibodies that target and neutralize circulating PCSK9. By inhibiting PCSK9, the therapy prevents the degradation of low-density lipoprotein (LDL) receptors on liver cells, thereby increasing the clearance of LDL cholesterol from the bloodstream. This platform aims to provide a long-acting, cost-effective alternative to traditional recombinant monoclonal antibody therapies like evolocumab and alirocumab.

Other names

DNA-encoded monoclonal antibody targeting PCSK9PCSK9 DMAbPCSK-9 DMAbPCSK 9 DMAb